DANIELI CASTRO OLIVEIRA DE ANDRADE

(Fonte: Lattes)
Índice h a partir de 2011
19
Lattes
ResearcherID
ORCID
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/17 - Laboratório de Investigação em Reumatologia, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

Autor: WILLIS, Rohan ×

Resultados de Busca

Agora exibindo 1 - 10 de 29
  • conferenceObject
    Antiphospholipid Antibody Profile Stability over Time: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (""Registry"")
    (2019) GKROUZMAN, Elena; SEVIM, Ecem; FINIK, Jackie; ANDRADE, Danieli; PENGO, Vittorio; SCIASCIA, Savino; TEKTONIDOU, Maria; UGARTE, Amaia; CHIGHIZOLA, Cecilia; BELMONT, H. Michael; SANCHEZ, Laura Perez; JI, Lanlan; FORTIN, Paul; EFTHYMIOU, Maria; JESUS, Guilherme De; BRANCH, David; NALLI, Cecilia; PETRI, Michelle; CERVERA, Ricard; ROD, Esther; KNIGHT, Jason; ATSUMI, Tatsuya; WILLIS, Rohan; BERTOLACCINI, Maria Laura; COHEN, Hannah; RAND, Jacob; ERKAN, Doruk
  • article 37 Citação(ões) na Scopus
    Characteristics of Patients With Antiphospholipid Antibody Positivity in the APS ACTION International Clinical Database and Repository
    (2022) SEVIM, Ecem; ZISA, Diane; ANDRADE, Danieli; SCIASCIA, Savino; PENGO, Vittorio; TEKTONIDOU, Maria G.; UGARTE, Amaia; GEROSA, Maria; BELMONT, H. Michael; ZAMORANO, Maria Angeles Aguirre; FORTIN, Paul R.; JI, Lanlan; EFTHYMIOU, Maria; COHEN, Hannah; BRANCH, D. Ware; JESUS, Guilherme Ramires; ANDREOLI, Laura; PETRI, Michelle; RODRIGUEZ, Esther; CERVERA, Ricard; KNIGHT, Jason S.; ATSUMI, Tatsuya; WILLIS, Rohan; ROUBEY, Robert; BERTOLACCINI, Maria Laura; ERKAN, Doruk; BARBHAIYA, Medha
    Objective To describe the baseline characteristics of patients with positivity for antiphospholipid antibodies (aPLs) who were enrolled in an international registry, the Antiphospholipid Syndrome (APS) Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository, overall and by clinical and laboratory subtypes. Methods The APS ACTION registry includes adults who persistently had positivity for aPLs. We evaluated baseline sociodemographic and aPL-related (APS classification criteria and ""non-criteria"") characteristics of patients overall and in subgroups (aPL-positive without APS, APS overall, thrombotic APS only, obstetric APS only, and both thrombotic APS/obstetric APS). We assessed baseline characteristics of patients tested for the presence of three aPLs (lupus anticoagulant [LAC] test, anticardiolipin antibody [aCL], and anti-beta(2)-glycoprotein I [anti-beta(2)GPI]) antibodies by aPL profiles (LAC only, single, double, and triple aPL positivity). Results The 804 aPL-positive patients assessed in the present study had a mean age of 45 +/- 13 years, were 74% female, and 68% White; additionally, 36% had other systemic autoimmune diseases. Of these 804 aPL-positive patients, 80% were classified as having APS (with 55% having thrombotic APS, 9% obstetric APS, and 15% thrombotic APS/obstetric APS). In the overall cohort, 71% had vascular thrombosis, 50% with a history of pregnancy had obstetric morbidity, and 56% had experienced at least one non-criteria manifestation. Among those with three aPLs tested (n = 660), 42% were triple aPL-positive. While single-, double-, and triple aPL-positive subgroups had similar frequencies of vascular, obstetric, and non-criteria events, these events were lowest in the single aPL subgroup, which consisted of aCLs or anti-beta(2)GPI only. Conclusion Our study demonstrates the heterogeneity of aPL-related clinical manifestations and laboratory profiles in a multicenter international cohort. Within single aPL positivity, LAC may be a major contributor to clinical events. Future prospective analyses, using standardized core laboratory aPL tests, will help clarify aPL risk profiles and improve risk stratification.
  • conferenceObject
    Clinical and Laboratory Characteristics of Antiphospholipid Antibody Positive Patients Included in the APS ACTION Registry
    (2019) SEVIM, Ecem; ZISA, Diane; ANDRADE, Danieli; SCIASCIA, Savino; GEROSA, Maria; BELMONT, H. Michael; EFTHYMIOU, Maria; FORTIN, Paul R.; LOPEZ-PEDRERA, Rosario; RODRIGUEZ, Esther; WILLIS, Rohan; ERKAN, Doruk; BARBHAIYA, Medha
  • article 36 Citação(ões) na Scopus
    The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody-Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository
    (2019) UNLU, Ozan; ERKAN, Doruk; BARBHAIYA, Medha; ANDRADE, Danieli; NASCIMENTO, Iana; ROSA, Renata; BANZATO, Alessandra; PENGO, Vittorio; UGARTE, Amaia; GEROSA, Maria; JI, Lanlan; EFTHYMIOU, Maria; BRANCH, D. Ware; JESUS, Guilherme Ramires de; TINCANI, Angela; BELMONT, H. Michael; FORTIN, Paul R.; PETRI, Michelle; RODRIGUEZ, Esther; PONS-ESTEL, Guillermo J.; KNIGHT, Jason S.; ATSUMI, Tatsuya; WILLIS, Rohan; ZUILY, Stephane; TEKTONIDOU, Maria G.
    Objective Although systemic lupus erythematosus (SLE) is the most common autoimmune disease associated with antiphospholipid antibodies (aPL), limited data exist regarding the impact of SLE on the clinical phenotype of aPL-positive patients. The primary objective of this study was to compare the clinical, laboratory, and treatment characteristics of aPL-positive patients with SLE with those of aPL-positive patients without SLE. Methods A secure web-based data capture system was used to store patient demographic characteristics and aPL-related clinical and laboratory characteristics. Inclusion criteria included positive aPL according to the updated Sapporo classification criteria. Antiphospholipid antibody-positive patients fulfilling the American College of Rheumatology criteria for the classification of SLE (""aPL with SLE"") and those with no other autoimmune diseases (""aPL only"") were included in the analysis. Results Six hundred seventy-two aPL-positive patients were recruited from 24 international centers; 426 of these patients did not have other autoimmune disease, and 197 had SLE. The frequency of thrombocytopenia, hemolytic anemia, low complement levels, and IgA anti-beta(2)-glycoprotein I (anti-beta(2)GPI) antibodies was higher in the aPL-positive patients with SLE, whereas the frequency of cognitive dysfunction and IgG anti-beta(2)GPI antibodies was higher in the aPL-only group. The frequency of arterial and venous thromboses (including recurrent) as well as pregnancy morbidity was similar in the 2 groups. The prevalence of cardiovascular disease risk factors at the time of entry into the registry entry did not differ between the 2 groups, with the exception of current smoking, which was more frequent in aPL-positive patients with SLE. Conclusion Although the frequencies of thrombosis and pregnancy morbidity are similar in aPL-positive patients with and those without SLE, the diagnosis of SLE in patients with persistently positive aPL is associated with an increased frequency of thrombocytopenia, hemolytic anemia, low complement levels, and positive IgA anti-beta(2)GPI antibodies.
  • conferenceObject
    Thrombocytopenia and Autoimmune Hemolytic Anemia in Antiphospholipid Antibody-positive Patients: Descriptive Analysis of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (""Registry"")
    (2022) ERTON, Zeynep Belce; LEAF, Rebecca K.; ANDRADE, Danieli Castro Oliveira de; BARBER, Megan; TEKTONIDOU, Maria G.; PENGO, Vittorio; SCIASCIA, Savino; UGARTE, Amaia; BELMONT, H. Michael; LOPEZ-PEDRERA, Chary; FORTIN, Paul R.; GEROSA, Maria; JESUS, Guilherme de; ATSUMI, Tatsuya; ZHANG, Zhuoli; COHEN, Hannah; BRANCH, D. Ware; WAHL, Denis; ANDREOLI, Laura; ALMARAZ, Esther Rodriguez; PETRI, Michelle; CERVERA, Ricard; ZUO, Yu Ray; ARTIM-ESEN, Bahar; WILLIS, Rohan; BERTOLACCINI, Maria Laura; ROUBEY, Robert; ERKAN, Doruk
  • conferenceObject
    The Clinical and Laboratory Characteristics of Antiphospholipid Antibody Positive Patients Included in the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (""Registry"")
    (2019) SEVIM, Ecem; ZISA, Diane; ANDRADE, Danieli; PENGO, Vittorio; SCIASCIA, Savino; TEKTONIDOU, Maria; UGARTE, Amaia; GEROSA, Maria; BELMONT, H. Michael; PEDRERA, Rosario Lopez; JI, Lanlan; FORTIN, Paul; EFTHYMIOU, Maria; JESUS, Guilherme De; BRANCH, David; ANDREOLI, Laura; PETRI, Michelle; CERVERA, Ricard; RODRIGUEZ, Esther; KNIGHT, Jason; ATSUMI, Tatsuya; WILLIS, Rohan; BERTOLACCINI, Maria Laura; COHEN, Hannah; ROUBEY, Robert; ERKAN, Doruk; BARBHAIYA, Medha
  • article 4 Citação(ões) na Scopus
    Damage measured by Damage Index for Antiphospholipid Syndrome (DIAPS) in antiphospholipid antibody-positive patients included in the APS ACTION registry
    (2024) BALBI, Gustavo G. M.; AHMADZADEH, Yasaman; TEKTONIDOU, Maria G.; PENGO, Vittorio; SCIASCIA, Savino; UGARTE, Amaia; BELMONT, H. Michael; LOPEZ-PEDRERA, Chary; FORTIN, Paul R.; WAHL, Denis; GEROSA, Maria; JESUS, Guilherme R. de; JI, Lanlan; ATSUMI, Tatsuya; EFTHYMIOU, Maria; BRANCH, D. Ware; NALLI, Cecilia; ALMARAZ, Esther Rodriguez; PETRI, Michelle; CERVERA, Ricard; KNIGHT, Jason S.; ARTIM-ESEN, Bahar; WILLIS, Rohan; BERTOLACCINI, Maria Laura; COHEN, Hannah; ROUBEY, Robert; ERKAN, Doruk; ANDRADE, Danieli Castro Oliveira de
    Objectives Our primary objective was to quantify damage burden measured by Damage Index for Antiphospholipid Syndrome (DIAPS) in aPL-positive patients with or without a history of thrombosis in an international cohort (the APS ACTION cohort). Secondly, we aimed to identify clinical and laboratory characteristics associated with damage in aPL-positive patients. Methods In this cross-sectional study, we analysed the baseline damage in aPL-positive patients with or without APS classification. We excluded patients with other autoimmune diseases. We analysed the demographic, clinical and laboratory characteristics based on two subgroups: (i) thrombotic APS patients with high vs low damage; and (ii) non-thrombotic aPL-positive patients with vs without damage. Results Of the 826 aPL-positive patients included in the registry as of April 2020, 586 with no other systemic autoimmune diseases were included in the analysis (412 thrombotic and 174 non-thrombotic). In the thrombotic group, hyperlipidaemia (odds ratio [OR] 1.82; 95% CI 1.05, 3.15; adjusted P = 0.032), obesity (OR 2.14; 95% CI 1.23, 3.71; adjusted P = 0.007), a & beta;(2)GPI high titres (OR 2.33; 95% CI 1.36, 4.02; adjusted P = 0.002) and corticosteroid use (ever) (OR 3.73; 95% CI 1.80, 7.75; adjusted P < 0.001) were independently associated with high damage at baseline. In the non-thrombotic group, hypertension (OR 4.55; 95% CI 1.82, 11.35; adjusted P = 0.001) and hyperlipidaemia (OR 4.32; 95% CI 1.37, 13.65; adjusted P = 0.013) were independent predictors of damage at baseline; conversely, single aPL positivity was inversely correlated with damage (OR 0.24; 95% CI 0.075, 0.77; adjusted P = 0.016). Conclusions DIAPS indicates substantial damage in aPL-positive patients in the APS ACTION cohort. Selected traditional cardiovascular risk factors, steroids use and specific aPL profiles may help to identify patients more prone to present with a higher damage burden.
  • conferenceObject
    Recurrent Thrombosis Risk in Non-anticoagulated Antiphospholipid Syndrome Patients: A Prospective Case-Control Study from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (""Registry"")
    (2022) YELNIK, Cecile; ERTON, Zeynep Belce; DRUMEZ, Elodie; CHEILDZE, Dachi; ANDRADE, Danieli Castro Oliveira de; CLARKE, Ann E.; TEKTONIDOU, Maria G.; PENGO, Vittorio; SCIASCIA, Savino; UGARTE, Amaia; BELMONT, H. Michael; AGUIRRE, Ma Angeles; FORTIN, Paul; GEROSA, Maria; SIGNORELLI, Flavio Victor; ATSUMI, Tatsuya; ZHANG, Zhouli; COHEN, Hannah; BRANCH, D. Ware; WAHL, Denis; ANDREOLI, Laura; ALMARAZ, Esther Rodriguez; PETRI, Michelle; CERVERA, Ricard; ZUO, Yu; ARTIM-ESEN, Bahar; PONS-ESTEL, Guillermo; WILLIS, Rohan; BERTOLACCINI, Maria Laura; ROUBEY, Robert; ERKAN, Doruk
  • article 268 Citação(ões) na Scopus
    14th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends
    (2014) ERKAN, Doruk; AGUIAR, Cassyanne L.; ANDRADE, Danieli; COHEN, Hannah; CUADRADO, Maria J.; DANOWSKI, Adriana; LEVY, Roger A.; ORTEL, Thomas L.; RAHMAN, Anisur; SALMON, Jane E.; TEKTONIDOU, Maria G.; WILLIS, Rohan; LOCKSHIN, Michael D.
    Antiphospholipid Syndrome (APS) is characterized by vascular thrombosis and/or pregnancy morbidity occurring in patients with persistent antiphospholipid antibodies (aPL). The primary objective of the APS Treatment Trends Task Force, created as part of the 14th International Congress on aPL, was to systematically review the potential future treatment strategies for aPL-positive patients. The task force chose as future clinical research directions: a) determining the necessity for controlled clinical trials in venous thromboembolism with the new oral direct thrombin or anti-factor Xa inhibitors pending the results of the ongoing rivaroxaban in APS (RAPS) trial, and designing controlled clinical trials in other forms of thrombotic APS; b) systematically analyzing the literature as well as aPL/APS registries, and creating specific registries for non-warfarin/heparin anticoagulants; c) increasing recruitment for an ongoing primary thrombosis prevention trial, and designing secondary thrombosis and pregnancy morbidity prevention trials with hydroxychloroquine; d) determining surrogate markers to select patients for statin trials; e) designing controlled studies with rituximab and other and-B-cell agents; f) designing mechanistic and clinical studies with eculizumab and other complement inhibitors; and g) chemically modifying peptide therapy to improve the half-life and minimize immunogenicity. The report also includes recommendations for clinicians who consider using these agents in difficult-to-manage aPL-positive patients.
  • article 17 Citação(ões) na Scopus
    Antiphospholipid Antibody Profile Stability Over Time: Prospective Results From the APS ACTION Clinical Database and Repository
    (2021) GKROUZMAN, Elena; SEVIM, Ecem; FINIK, Jackie; ANDRADE, Danieli; PENGO, Vittorio; SCIASCIA, Savino; TEKTONIDOU, Maria G.; UGARTE, Amaia; CHIGHIZOLA, Cecilia B.; BELMONT, H. Michael; LOPEZ-PEDRERA, Chary; JI, Lanlan; FORTIN, Paul; EFTHYMIOU, Maria; JESUS, Guilherme Ramires de; BRANCH, D. Ware; NALLI, Cecilia; PETRI, Michelle; RODRIGUEZ, Esther; CERVERA, Ricard; KNIGHT, Jason S.; ATSUMI, Tatsuya; WILLIS, Rohan; BERTOLACCINI, Maria Laura; COHEN, Hannah; RAND, Jacob; ERKAN, Doruk
    Objective. The APS ACTION Registry studies long-term outcomes in persistently antiphospholipid anti-body (aPL)-positive patients. Our primary objective was to determine whether clinically meaningful aPL profiles at baseline remain stable over time. Our secondary objectives were to determine (1) whether baseline characteristics differ between patients with stable and unstable aPL profiles, and (2) predictors of unstable aPL profiles over time. Methods. A clinically meaningful aPL profile was defined as positive lupus anticoagulant (LAC) test and/or anticardiolipin (aCL)/anti-beta(2) glycoprotein-I (anti-(beta(2)-GPI) IgG/M >= 40 U. Stable aPL profile was defined as a clinically meaningful aPL profile in at least two-thirds of follow-up measurements. Generalized linear mixed models with logit link were used for primary objective analysis. Results. Of 472 patients with clinically meaningful aPL profile at baseline (median follow-up 5.1 yrs ), 366/472 (78%) patients had stable aPL profiles over time, 54 (11%) unstable, and 52 (11%) inconclusive. Time did not significantly affect odds of maintaining a clinically meaningful aPL profile at follow-up in univariate (P= 0.906) and multivariable analysis (P= 0.790). Baseline triple aPL positivity decreased (OR 0.25, 95% CI 0.10-0.64, P = 0.004) and isolated LAC test positivity increased (OR 3.3, 95% CI 1.53-7.13, P = 0.002) the odds of an unstable aPL profile over time. Conclusion. Approximately 80% of our international cohort patients with clinically meaningful aPL profiles at baseline remain stable at a median follow-up of 5 years; triple aPL-positivity increase the odds of a stable aPL profile. These results will guide future validation studies of stored blood samples through APS ACTION Core Laboratories.